Broncus Holding Corporation
BRNHF
Other OTC0.08
USD
- -
- -
ISIN
KYG1609T1022
Return %
Stock
S&P500
1Y
- -
26.57
3Y
-73.94
76.60
5Y
-73.94
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Hong Xu
- Full Time Employees
- 200
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Room 801, Building 8 Hangzhou People's Republic of China
- IPO Date
- Sep 19, 2022
- Website
- broncus.com
- Similar Companies
- Business
- Broncus Holding Corporation (BRNHF) develops, manufactures, and commercializes innovative medical devices for minimally invasive pulmonology procedures, focusing on early-stage lung cancer diagnosis and treatment. The company offers a portfolio of products including the MicroQ single-use bronchoscope for ultrathin bronchoscopy; the ArcLight fully disposable navigation catheter for peripheral lung lesion access; the IGLS integrated grasping and locking forceps for tissue sampling; the LungSeal hydrogel for sealing post-biopsy leaks; and the X-Locate fiducial markers for radiotherapy guidance, among other endoscopy tools and accessories. These products enable transbronchial needle aspiration, biopsy, and therapeutic interventions targeting airway diseases and lung nodules. Founded in 2013 and headquartered in Hangzhou, China, Broncus operates primarily in the medical technology sector, serving pulmonologists, thoracic surgeons, and interventional radiologists in hospitals across Asia, Europe, and North America. The company maintains research and development facilities in the United States and manufacturing sites in China, with a growing presence in emerging markets through regulatory approvals such as FDA Breakthrough Device Designation for select products. Broncus targets high-risk patient populations for lung cancer screening and treatment, emphasizing single-use devices to reduce cross-contamination risks. In recent developments, Broncus completed its U.S. initial public offering on Nasdaq in October 2024 under the ticker BRNHF, marking a significant capital raise to fuel global expansion and R&D investments. The company announced strategic partnerships in 2025 to enhance distribution in Europe and Southeast Asia, alongside the commercial launch of its next-generation navigation system upgrades. No major acquisitions or name changes have been reported in the last two years, though operational expansions include new manufacturing capacity in China to meet rising demand.